On the morning of June 4, Yantai Biomedical Group, together with 15 resident enterprises and 2 partner units from Blue Pharma Valley · Life Island Park — gathering more than 70 participants — held the launch ceremony for the 2026 "Work Safety Month" activities
Recently, Yantai Biomedical Group traveled to Suzhou to attend the 7th International Cell and Gene Therapy China Summit & Exhibition (CGCS 2026), where it carried out promotional activities including park presentations and booth exhibitions for Yantai Blue Pharma Valley · Life Island Park.
Yantai Biomedical Health Industry Development Group Co., Ltd., a wholly-owned subsidiary of Yantai Guofeng Investment Holding Group Co., Ltd., has recently been assigned a corporate credit rating of AA+ with a stable outlook by Golden Credit Rating International Co., Ltd.
The theme of this conference is "Capital Empowered Industry Co prosperity". More than 300 leaders and representatives from scientific research institutes, medical enterprises, investment institutions, financial institutions and other fields participated in the conference, jointly conducting academic exchanges, exploring industrial development directions, showcasing innovative achievements in biopharmaceuticals, and discussing cooperation strategies.